Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Starpharma VivaGel®-coated condom approved for marketing in Japan

Abstract:
Starpharma  (ASX:  SPL,  OTCQX:  SPHRY)  today  announced  that  regulatory  certification  has  been  granted  for  marketing  Starpharma's  VivaGel®‐coated condom in Japan, the world's second largest condom market. 

Starpharma VivaGel®-coated condom approved for marketing in Japan

Melbourne,  Australia | Posted on March 14th, 2014

VivaGel® is licensed to Okamoto Industries (TSE: JP3192800005) as a condom coating for the 
Japanese market. Okamoto is the market leader for condoms sold in Japan and has held this 
position for many years. Under Starpharma's commercial licence agreement with Okamoto, 
Okamoto  has  exclusive  Japanese  marketing  rights  for  the  VivaGel®‐coated  condom. 
VivaGel®‐coated condoms sold by Okamoto will carry the VivaGel® brand and Starpharma 
will receive royalties based on sales of these condoms.  
 
"This receipt of the world's first marketing approval for a VivaGel®‐coated condom in Japan 
marks a major milestone for this product and for our strategically important partnership 
with Okamoto. We greatly appreciate Okamoto's support and assistance in achieving this 
certification and we look forward to a long and mutually profitable commercial relationship" 
said Starpharma CEO, Dr Jackie Fairley. 
 
"Following this certification Starpharma looks forward to the introduction of its innovative, 
patented VivaGel®‐coated condom to this key market in partnership with Okamoto, one of 
the world's leading condom companies," she added. 

Okamoto is Japan's leading marketer of condoms with approximately 60% share of the 
Japanese condom market. The value of the Japanese condom market has been estimated to 
be in the order of US$500 million.  Okamoto, based in Tokyo, has total revenues of more 
than US$740 million and over 1,500 employees.  In addition to its dominant position in the 
Japanese condom market, Okamoto also holds strong market positions in several other 
Asian markets, including Korea, Taiwan, Malaysia, Singapore and China. 

Okamoto's  senior  managing  director  Mr.  Seiji  Takeuchi  said  in  January  this  year  that 
condoms with functional coatings and gels represent the next wave of innovation in the 
Japanese condom market following on from a decades‐long focus on condom thinness.  
 
Following this initial VivaGel®‐coated condom certification, Mr Takeuchi said, "We are very 
pleased to be in a partnership with Starpharma for this product." 

Starpharma  has  a  separate  licensing  agreement  with  Ansell  Limited  (ASX:  ANN)  which 
provides marketing rights to a VivaGel®‐coated condom in countries outside Japan and the 
company looks forward to further regulatory approvals under that partnership. 
 
VivaGel® 

Starpharma's  VivaGel®  active  (SPL7013)  has  both  antibacterial  and  antiviral  properties  and  in 
laboratory studies has been shown to kill 99.9% of HIV, HPV (human papillomavirus) and HSV‐2 
(genital herpes virus). VivaGel® is also being separately developed as an applicator‐delivered vaginal 
product for the management of bacterial vaginosis. 

####

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma’s lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV). Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca. A number of dendrimer-enhanced, or DEP™ versions of existing drugs are under development. The most advanced of these is DEP™ docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®) which is in clinical development. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals Starpharma has a series of partnerships with leading industry players including Nufarm (ASX:NUF) and Makhteshim Agan as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma’s business, which can be
identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”,
“believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could
provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied
discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from any future results, performance or achievements expressed or
implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy
the FDA’s and other authorities’ requirements regarding any one or more product candidates nor can there be
any assurance that such product candidates will be approved by any authorities for sale in any market or that
they will reach any particular level of sales. In particular, management’s expectations regarding the approval and
commercialization of the product candidates could be affected by, among other things, unexpected trial results,
including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or
government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property
protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results
and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those described herein as anticipated,
believed, estimated or expected. Starpharma is providing this information as of the date of this document and
does not assume any obligation to update any forward-looking stateof new information, future events or developments or otherwise.

For more information, please click here

Contacts:
Media:
Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391


Starpharma:

Dr Jackie Fairley
Chief Executive Office
+61 3 8532 2704
Nigel Baade
CFO and Company Secretary

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Govt.-Legislation/Regulation/Funding/Policy

Study finds physical link to strange electronic behavior: Neutron measurements offer new clues about iron-based superconductor July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Nanomedicine

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

Announcements

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Patents/IP/Tech Transfer/Licensing

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Bruker Awarded Fourth PeakForce Tapping Patent: AFM Mode Uniquely Combines Highest Resolution Imaging and Material Property Mapping July 22nd, 2014

Rice's silicon oxide memories catch manufacturers' eye: Use of porous silicon oxide reduces forming voltage, improves manufacturability July 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE